Abstract: Scaffolds for use in bone tissue engineering include a skeleton and a host component. Methods of preparation of scaffolds include identification of biodegradation properties for the skeleton and the host component. The skeleton is constructed to form a three-dimensional shape. The skeleton is constructed of a first material and has a first rate of biodegradation. The host component fills the three-dimensional shape formed by the skeleton. The host component is constructed of a second material and has a second rate of biodegradation. The first rate of biodegradation is slower than the second rate of biodegradation.

Abstract: A pharmaceutical active-containing transmucosal delivery device comprises a polymer film comprising a polymer matrix, wherein the film has a pH in the range of about 4 to about 9, and a pharmaceutical active composition disposed on a surface of the polymer film. The composition comprises at least one pharmaceutical active ingredient in the form of particles, and wherein the particles have an average particle size of about 100 nm to about 5 microns, an anti-crystallization agent, and a pH adjusting agent, wherein the concentration of the pharmaceutical active ingredient is at least 20% w/w relative to the total weight of the pharmaceutical active composition. The delivery device exhibits a residence time in the mouth of a subject ranging from about 5 minutes to about 30 minutes and is substantially mucoadhesive to a mucosa surface when placed sublingually under the tongue or placed buccally at the inner lining of the cheek.

Abstract: Provided herein are microspheres containing an antimicrobial agent encapsulated within a glycosidic polymer and use thereof, especially to inhibit the growth of carie-causing organism.

Abstract: Disclosed is a dissolvable, gel-forming film, and methods for its use, comprising a water-soluble cellulose ether, a hydrophilic rheological modifying agent, and an active proteolytic enzyme or other drug substance. The gel-forming film has a water content of less than 15% w/w and is capable of forming a hydrogel when contacted with water or other aqueous medium. The disclosed films achieve delivery of stable proteolytic enzymes to the desired site of action in a manner that provides uniform delivery of the enzymes.

Abstract: Collagen matrix granulate blend, and process for making and using a collagen matrix or granulate blend including collagen and particles of a biphasic calcium phosphate/hydroxyapatite (CAP/HAP) bone substitute material having a sintered CAP core and having its total external surface covered by at least one closed epitactically grown layer of nanocrystalline HAP deposited on the external surface of the sintered CAP core, whereby the epitactically grown nanocrystals have the same size and morphology as human bone mineral, wherein the closed epitactically grown layer of nanocrystalline HAP is transformed from the CAP on the external surface of the sintered CAP core has a non-homogeneous external surface comprising individual clusters of flat crystal platelets consisting of epitactically grown HAP nanocrystals and coarse areas between the individual clusters, whereby the percentage of the coarse areas between the individual clusters as measured by SEM is at least 20% of the total surface.

Abstract: Non-woven graft materials for use in specialized surgical procedures such as neurosurgical procedures, methods for making the non-woven graft materials, and methods for repairing tissue such as neurological tissue using the non-woven graft materials are disclosed. More particularly, disclosed are non-woven graft materials including at least two distinct fiber compositions composed of different polymeric materials, methods for making the non-woven graft materials and methods for repairing tissue in an individual in need thereof using the non-woven graft materials.

Abstract: Cells derived from postpartum tissue and methods for their isolation and induction to differentiate to cells of a chondrogenic or osteogenic phenotype are provided by the invention. The invention further provides cultures and compositions of the postpartum-derived cells and products such as lysates related thereto. The postpartum-derived cells of the invention and products related thereto have a plethora of uses, including but not limited to research, diagnostic, and therapeutic applications, for example, in the treatment of bone and cartilage conditions such as osteoarthritis.

Abstract: The present invention provides an aqueous patch which can stably contain only one of an S-enantiomer and an R-enantiomer of a drug capable of being present in such enantiomers at a relatively high concentration over a long period of time, has the excellent adhesive property and the excellent shape retaining property, and achieves high skin permeability of the drug. Specifically, the present invention provides an aqueous patch containing only one of enantiomers of a drug as an active ingredient in a pasty preparation.

Abstract: A soft film, a sponge, or a sheet in the dried state is provided, which is capable of forming a hydrogel absorbing water or blood. The film is obtainable by preparing a film-state material in the dried state from either a solution of poly(acrylic acid) or a solution of polyvinylpyrrolidone, and bringing the film-state material into contact with the other remaining solution, and then drying or freeze-drying it.

Abstract: An article comprising a macroporous wound-packing material and a microcorrugated microporous wound-contact layer is provided. The wound packing material is coupled to and/or substantially surrounded by the wound-contact layer. The average pore diameter of the microporous layer is less than or equal to about 90 m. A method of treating a wound using a microcorrugated microporous wound-contact layer and a macroporous wound packing material is also provided.

Abstract: The antiseptic wound dressing includes at least nanometer chitin, alkaline earth metal alginate, and an antiseptic material. The nanometer chitin is tubular shaped having diameter 10˜50 nm and length 20˜200 nm. The amount of the nanometer chitin is 0.1%˜5% to the alkaline earth metal alginate. The antiseptic wound dressing is manufactured by mixing nanometer chitin and alkaline metal alginate, further mixing with antiseptic material, conducting a wet spinning process to produce fibers, and conducting a non-woven cloth process to obtain the antiseptic wound dressing of the present invention. Therefore, the antiseptic wound dressing is capable of reducing the chance of would infection, and providing superior moisture retention and enhanced wet strength.

Abstract: There is provided a depot suitable for sustained-release drug delivery, said depot including a composite body comprising particles having at least one encapsulated active pharmaceutical ingredient The depot includes 50 to 95 wt % of the composite body particles, said composite body particles having 0.1 to 80 wt % of active pharmaceutical ingredient, and the active pharmaceutical ingredient is a non-steroidal anti-inflammatory drug. In addition, the composite body is formed of a silica hydrogel comprising the silica particles.

Abstract: The described invention provides a topical delivery system comprising a pharmaceutical composition for application directly to a skin of a subject in need thereof comprising (a) an effective therapeutic amount of an active therapeutic agent; (b) chemical drivers comprising an amino benzoate local anesthetic, ethoxydiglycol and methylsulfonylmethane (MSM) that in combination are effective to synergistically deliver the therapeutic agent; and (c) a depot component for keeping the pharmaceutical composition in the skin. Methods for delivering an active therapeutic agent into skin, for keeping it in the skin, for reducing systemic side effects attributable to entry of the active agent into the blood stream, and a method for treating a condition, disease or disorder of skin topically also are described in accordance with the embodiments of the described invention.

Abstract: An anti-adhesion composition with a good anti-adhesion property as well as a good biocompatibility, a surgical mesh composite with anti-adhesion property comprising the same and method for producing the same are provided.

Abstract: The invention relates to a polymer material comprising a mixture of: a base polylactic acid (PLA) polymer formed by between 60 wt.-% and 85 wt.-% L units and between 15 wt.-% and 40 wt.-% D units or between 60 wt.-% and 85 wt.-% D units and between 15 wt.-% and 40 wt.-% L units; and a plasticizer selected from the group containing citric acid esters, glycerin esters and derivatives, poly(alkylene ethers), oligomers of lactide or derivatives of lactic acid, fatty acid esters and epoxidized oils, representing between 10 wt.-% and 40 wt.-% in relation to the total weight of the polymer material.

Abstract: A method for manufacturing an implantable film and a prosthesis comprising such a film The present invention relates to a method for manufacturing a non porous film intended to be implanted in the human body, said method comprising the following steps: preparation of a first film, called intermediate film, via gelling of a starting solution comprising at least one polymer selected in the group consisting of collagen, glycosaminoglycans, and mixtures thereof, immersion of said intermediate film in an alkaline composition comprising at least one C1-C4 alcohol, drying of the film obtained at the end of the immersing step. The invention also relates to a method for manufacturing a prosthesis comprising a textile support and such a film.

Abstract: Skin regeneration or grafting is promoted utilizing a structure including a multi-layer sheet of collagen membrane material which includes a purified collagen barrier sheet material derived from natural collagen-containing tissue, the barrier sheet material including a barrier layer with an outer smooth barrier face and a fibrous face opposite the smooth barrier face. The structure further includes a matrix layer of collagen sponge material adjacent to the fibrous face. The matrix layer of collagen sponge material is resorbed by a body of a subject at a substantially faster rate than the barrier sheet material.

Abstract: A poly(ester amide) polymer having free carboxylic acid pendant groups and method of making and using the same are disclosed.

Abstract: Bioerodable poly(etheresteramides) and matrices formed therefrom, such as medical device coatings, are described. The matrices show desirable erosion properties desirable for therapeutic use. The matrices can include a bioactive agent which can be used to treat medical conditions.

Abstract: Silica nanopowders with biocidal properties, especially for polymer composites, are produced by sol-gel method. The silica sol is produced from the aqueous mixture containing tetraalkoxysilane, in which alkoxy group contains from C1 to C4 carbon atoms, an alcohol or the mixture of aliphatic alcohols from C1 to C4, in the mole ratio of 1:5 to 1:35, in the presence of ammonium compound, used in an amount of from 0.001 to 0.05 mol per 1 mol of tetraalkoxysilane, with introducing, after thorough mixing of components, the silver salt in the form of aqueous solution in an amount from 0.02 to 1 mol per 1 mol of tetraalkoxysilane, and subsequently the aqueous solution of alkali metal hydroxide in an amount from 0.02 to 1 mol of hydroxide per 1 mol of tetraalkoxysilane.

Abstract: A method of making a composition comprising reacting (a) an isocyanate group-containing component having an average functionality of at least 2; and (b) an active hydrogen group-containing component having an average functionality of at least 2 to form a composition that is biodegradable, a solid at 22° C. and below, and has pressure sensitive adhesive properties at a temperature of 37° C. and relative humidity of 100%. A method of using the composition therefore to adhere polymer meshes or films to biological tissue is also disclosed.

Abstract: The invention provides disintegratable adhesive films containing a mixture of high molecular weight and low molecular weight water soluble components; and a pharmaceutically or cosmetically active ingredient. Optionally, the films contain a starch component, a polysaccharide component, a filler, a plasticizer and/or humectant. The films are preferably in the form of an adhesive layer having a thickness sufficient to disintegrate, when exposed to a moist environment and/or a trigger compound, and release the active ingredient. The films can be cut to any desired size or shape to provide conveniently useable unit dosage forms for administration to wet or moist body surfaces for human, pharmaceutical, cosmetic, or veterinary applications. The invention further provides various end uses and methods of administering the film compositions.

Abstract: A laminate and process of making the laminate is disclosed comprising: a surgical mesh having first and second surfaces; and an adhesive structure having adhesive and non-adhesive surfaces, wherein the non-adhesive surface of the adhesive structure is laminated to at least one of said first and second surfaces of said surgical mesh, and the adhesive surface of said adhesive structure has protrusions extending therefrom comprising a resin having a Young's modulus of greater than 17 MPa, which protrusions are of sufficiently low diameter to promote adhesion by increasing physical attractive forces between the adhesive structure and a target surface, as measured by shear adhesion.

Abstract: A transdermal composition comprising ibuprofen or salts thereof and a gelling agent which can be used for the treatment of such disorders as pain, inflammation, arthritis, muscle spasm and associated symptoms in humans and animals.

Abstract: The present invention provides a hemostatic porous sponge comprising a matrix of a fibrous biomaterial and particles of a fluid absorbing, particulate material adhered to said matrix material, a method of producing these sponges and their use for wound healing.

Abstract: Disclosed are solid dressings for treated wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of fibrinogen and a fibrinogen activator, wherein the fibrinogen is present in an amount between 3.0 mg/cm2 of the wound facing surface of the dressing and 13.0 mg/cm2 of the wound facing surface of the dressing. Also disclosed are methods for treating wounded tissue.

Abstract: A medicament carrier composition includes a medicament and a polymer component including a polyvinylpyrrolidone having a weight average molecular weight of at least 700,000 g/mol. The medicament carrier composition has a viscosity of from 500 to 5,000 cps at 250 C, is substantially free of cellulose, and includes an auxiliary polymer. The medicament carrier composition is used to form a film that is also substantially free of cellulose. The film has a consistent thickness and size, and an increased flexibility and increased moisture resistance due to the polyvinylpyrrolidone. The medicament carrier composition is also used in a method of forming the film. The method includes the steps of providing the medicament and the polymer component. The method also includes the step of combining the polymer component and the medicament to form the medicament carrier composition. The method further includes the step of drying the medicament carrier composition to form the film.

Abstract: Disclosed are solid dressings for treated wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of a fibrinogen component and thrombin, wherein the thrombin is present in an amount between 0.250 Units/mg of fibrinogen component and 0.062 Units/mg of fibrinogen component. Also disclosed are methods for treating wounded tissue.

Abstract: Compositions and methods for treating and healing injured soft tissues such as tendons and ligaments are provided. The composition may be a wrap comprising human collagen in the form of a sheet. The human collagen has been processed so that is retains proteins that are associated with it in its natural state. The sheet may optionally be coated on one or more sides with one or more of additional human collagen, therapeutic agents, additional soft tissue growth factors or hydroxyapatite.

Abstract: A dissolving oral adhering patch with a dimple on at least one side to improve adhesion to hard convex surfaces in the mouth, including teeth, orthodontic braces and gums (keratinized gingiva). The patch may be designed to prevent or treat a sore in the mouth opposite a tooth or brace and may release a medication into the mouth, to treat a sore or to treat or prevent conditions elsewhere in the mouth or throat or stomach.

Abstract: Biocompatible foams having excellent physical and chemical properties are described. The biocompatible foams can be formed in situ or applied as a pre-formed foam for the treatment of tissue. The invention provides biocompatible degradable foams formed with a poly-?(1?4)glucopyranose macromer. The invention also provides biostable foams formed with a poly(alkylene oxide) macromer.

Abstract: Methods for sealing a puncture communicating with a blood vessel are provided that include introducing a porous carrier formed from lyophilized hydrogel or other material into the puncture. The plug may include at least first and second hydrogel precursors and a pH adjusting agent carried by the porous carrier in an unreactive state prior to exposure to an aqueous physiological environment. Once exposed to bodily fluids, the carrier expands as the lyophilized material hydrates to enhance and facilitate rapid hemostasis of the puncture. When the plug is placed into the puncture, the natural wetting of the plug by bodily fluids (e.g., blood) causes the first and second precursors to react and cross-link into an adhesive or “sticky” hydrogel that aids in retaining the plug in place within the puncture.

Abstract: A composition comprising the reaction product of (a) an isocyanate group-containing component having an average functionality of at least 2; and (b) an active hydrogen group-containing component having an average functionality of at least 2. The composition is biodegradable, a solid at 22° C. and below, and has pressure sensitive adhesive properties at a temperature of 37° C. and relative humidity of 100%. The composition may be used to adhere polymer meshes or films to biological tissue.

Abstract: A blood product (10), a method for preparing the blood product, a blood product obtainable by the method and a blood product preparing container means. The blood product comprises components from whole blood, especially fibrin, thrombocytes and leukocytes. The blood product (10) comprises a first layer (21), a second layer (22) and a third layer (23). The second layer (22) is adjacent to the first layer (21) and the third layer (23). The first layer (21) defines a first outer surface (24) of the blood product (10) and the third layer (23) defining a second outer surface (25) of the blood product (10). The first layer (21) comprises a majority of fibrin, the second layer (22) comprises a majority of thrombocytes and the third layer (23) comprises a majority of leukocytes.

Abstract: Disclosed are tissue graft compositions made of materials having different densities, methods of making, and methods of treatment for restoring tissues in a patient.

Abstract: This invention provides novel nanofiber enhanced surface area substrates and structures comprising such substrates for use in various medical devices, as well as methods and uses for such substrates and medical devices. In one particular embodiment, methods for enhancing cellular functions on a surface of a medical device implant are disclosed which generally comprise providing a medical device implant comprising a plurality of nanofibers (e.g., nanowires) thereon and exposing the medical device implant to cells such as osteoblasts.

Abstract: The present invention relates generally to agents and devices for promoting hemostasis and tissue sealing and, more particularly, to hemostatic pads comprising bioabsorbable scaffolds that can deliver lyophilized hemostasis promoting proteins, such as fibrinogen and thrombin, to a wound site or injured organ or tissue.

Abstract: A medicant composition is provided. The composition includes a film layer and a powder matrix layer. The powder matrix layer includes a medicant. The powder matrix layer is applied to the film layer by admixing particulate to form a powder matrix and by then applying the powder matrix to the film layer by any desired method. The composition of the powder matrix is varied to alter the dissolution rate of the medicant, the adhesion of the medicant composition, and other physical properties of the powder matrix. The powder matrix layer can be cured.

Abstract: In embodiments of the present invention, a biodegradable/biodegradable polymer film may be used as a scaffold for tissue engineering scaffolds for engineering organized organs, such as vascular grafts, for example. In one embodiment, an ultraviolet (UV) resin made from a diacrylated biodegradable oligomer is molded into a flexible scaffold having cavities and/or channels. Channel/cavity size may be on the order of micrometers and/or nanometers, and thus the walls may have high aspect ratios. Smooth muscle cells may be deposited in the channels and because of the high aspect ratios, the cells may align along the channels/cavities as confluence is reached.

Abstract: Drug-eluting devices and methods for the treatment of tumors of the pancreas, biliary system, gallbladder, liver, small bowel, or colon, are provided. Methods include deploying a drug-eluting device having a film which includes a mixture of a degradable polymer and a chemotherapeutic drug, wherein the film has a thickness from about 2 ?m to about 1000 ?m, into a tissue site and releasing a therapeutically effective amount of the chemotherapeutic drug from the film to treat the tumor, wherein the release of the therapeutically effective amount of the drug from the film is controlled by in vivo degradation of the polymer at the tissue site.

Abstract: Methods, system and compositions for making and using a bioresorbable linked dressing made of bioresorbable microspheres in various configurations are provided for use in applying reduced pressure to a wound site. The methods include manufacture of a bioresorbable dressing comprising a casing and bioresorbable microspheres in the form of a rope shape. Further, the casing of the dressing comprises pores formed by a porogen system that may be activated by external to the wound or formed in situ within the wound site. The shape of the dressing allows the dressing to be placed into the wound site such that it fills the shape and size of the wound. Embodiments include formation of various rope dressing and their use in conjunction with reduced pressure therapy.

Abstract: A hemostatic device for promoting the clotting of blood includes a gauze substrate, a clay material disposed on the gauze substrate, and also a polyol such as glycerol or the like disposed on the gauze substrate to bind the clay material. When the device is used to treat a bleeding wound, at least a portion of the clay material comes into contact with blood emanating from the wound to cause the clotting. A bandage that can be applied to a bleeding wound to promote the clotting of blood includes a flexible substrate and a gauze substrate mounted thereon. The gauze substrate includes a clay material and a polyol. A hemostatic sponge also includes a gauze substrate and a dispersion of hemostatic material and a polyol on a first surface of the substrate.

Abstract: A composition for delivery of a molecule into a cell is provided. The composition includes a protein transduction domain that is conjugated to the molecule which is incorporated into a multilayered film. Preferably, the protein transduction domain is a cationic protein transduction domain. More preferably, the cationic protein transduction domain is nonaarginine, and the multilayered film includes polyelectrolyte multilayers. When the composition is presented to a cell, the multilayered film dissolves or erodes in physiological media, and the molecule is delivered into the cell.

Abstract: Disclosed is a biocompatible, hemostatic, cross-linked gelatin composition comprising a biocompatible material comprising cross-linked gelatin and a sufficient amount of wetting agent to permit uniform wetting of the sponge in the presence of an aqueous solution.

Abstract: An enhanced article which has a beneficial contact surface intended to allow bioabsorption of beneficial materials through the user's contact with the enhanced article in use. A functional or ornamental article which has at least one contact surface intended to come in contact with a human user includes a beneficial contact surface for covering the article's contact surface and providing a beneficial surface contact compound adapted to come in contact with a human user touching the article. The beneficial contact surface is connected to the article so that the contact surface of the article is covered by the beneficial contact surface. The presence of the beneficial surface contact compound in the beneficial contact surface means results in the exposure of the user's skin to the beneficial surface contact compound to allow absorption by the user.

Abstract: A biocompatible material may be configured into any number of implantable medical devices including a vascular closure device. The vascular closure device includes a fibrous structure formed from at least one randomly oriented fiber, the randomly oriented fiber comprising at least one polymer, and at least one agent, in therapeutic dosage, incorporated into at least one of the fibrous structure and the at least one randomly oriented fiber.

Abstract: A device for promoting the clotting of blood comprises a clay material in particle form and a receptacle for containing the clay material. At least a portion of the receptacle is defined by a mesh. Another device comprises a gauze substrate and a clay material disposed on the gauze substrate. Another device is a bandage comprising a substrate, a mesh mounted on the substrate, and particles of a clay material retained in the mesh. A hemostatic sponge comprises a substrate, a hemostatic material disposed on a first surface of the substrate, and a release agent disposed on a second surface of the substrate. The release agent is disposed on the wound-contacting surface of the substrate. When treating a bleeding wound, application of the hemostatic sponge causes at least a portion of the hemostatic material to come into contact with blood through the release agent and through the substrate.

Abstract: A fibrin wound dressing is made by mixing quantities of fibrinogen solution and thrombin solution with air. The resulting foam is very light weight, and with the proper attention to the amount of thrombin, is also sufficiently viscous to rest on a vertical surface without dripping. The wound dressing may also be formulated for its ability to continue migration of healing substances, such as PDGF, from the dressing to the wound site. Thrombin substitutes, such as other clotting proteins, may be used instead of thrombin. The resulting foam may also be lyophilized or ground and lyophilized for later reconstitution. A therapeutic drug or other additive may also be added to the wound dressing.

Abstract: Provided is an adhesion preventing medical material including a bioresorbable base material and a polyhydric alcohol or aqueous polyhydric alcohol solution, which contains the polyhydric alcohol, held in the bioresorbable base material. The bioresorbable base material includes a bioresorbable material, and has a swelling degree of 200 to 3,000 mass % and a water elution rate of not higher than 10 mass %. After immersed for 3 hours in water of 25° C. in an amount at least 50 times a total mass of the aqueous polyhydric alcohol solution or aqueous polyhydric alcohol solution and the bioresorbable base material, the polyhydric alcohol remains in an amount of not greater than 30 mass % of that of the polyhydric alcohol before the immersion.

Abstract: An antiadhesive material that is excellent in biocompatibility and bioabsorbability, as well as excellent strength in suturing and bonding, is provided. A reinforcing material 12 made of a biodegradable polymer is placed in a gelatin solution so that the reinforcing material 12 is impregnated with the solution, and the gelatin is caused to gelate and dried. By so doing, an antiadhesive material in which a gelatin film 11 and the reinforcing material 12 are integrated is obtained. The reinforcing material 12 preferably is arranged in a portion of the gelatin film 11 to be subjected to suturing, and preferably is arranged along a periphery of the gelatin film 11. The gelatin film 11 preferably is a cross-linked gelatin film, and the reinforcing material 12 preferably is a nonwoven fabric.